SEC Filing Summary: AspenBio Pharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on May 7, 2009. The registrant is incorporated in Colorado and maintains its principal executive offices in Castle Rock, CO. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate profile updates rather than a financial statement.
Material Changes
The primary material event reported is the update of the Company's Corporate Profile information. This updated profile is furnished as Exhibit 99.1 and incorporated by reference under Item 7.01 (Regulation FD Disclosure).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or specific discussion of risks and contingencies. The document solely references the availability of the updated Corporate Profile on the Company's website.
Key Facts for Investor Verification
- Verify the contents of the updated Corporate Profile (Exhibit 99.1) referenced in the filing.
- Confirm the filing date of May 7, 2009, and the identity of the signatory, Jeffrey G. McGonegal, Chief Financial Officer.
- Note that this filing does not contain financial performance data; investors should refer to periodic reports (10-K or 10-Q) for financial metrics.